Tandem Diabetes Care Announces Upcoming Conference Presentations

Rhea-AI Summary

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced its participation in several upcoming investor conferences. Key presentations will take place at the Citi Healthcare Services Conference on March 2, Cowen Healthcare Conference on March 6, Raymond James Conference on March 8, Oppenheimer Healthcare Conference on March 13, and Barclays Global Healthcare Conference on March 14. Each presentation will be webcast live, with an archive available for 30 days on their Investor Center website. Tandem Diabetes focuses on innovative insulin delivery solutions, including the t:slim X2 insulin pump.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

• Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Thursday, March 2, 2023 at 2:45pm ET (11:45am PT),
• Cowen 43^rd Annual Health Care Conference on Monday, March 6, 2023 at 12:50pm ET (9:50am PT),
• Raymond James & Associates’ 44^th Annual Institutional Investors Conference on Wednesday, March 8, 2023 at 9:50am ET (6:50am PT),
• Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13, 2023 at 8:40am ET (5:40am PT), and
• Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 11:15am ET (8:15am PT).

The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care and Control-IQ are trademarks registered in the U.S. and/or other countries and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005539/en/

Media Contact:

858-255-6388

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.

FAQ

When will Tandem Diabetes Care present at investor conferences?

Tandem Diabetes Care will present at various conferences from March 2 to March 14, 2023.

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care's stock symbol is TNDM.

Where can I watch the Tandem Diabetes Care conference presentations?

The presentations can be watched live and archived on Tandem Diabetes Care's Investor Center website.

What key product does Tandem Diabetes Care offer?

Tandem Diabetes Care offers the t:slim X2 insulin pump, which features Control-IQ technology.

What is the purpose of the Tandem Diabetes Care presentations?

The presentations will provide updates about the company and its products to investors.